CD19 and autoimmune disease: Basu and colleagues show CABA-201, a B cell-targeting CAR T cell product with a fully human CD19 binder and 4-1BB costimulatory domain, can precisely eliminate autoimmune patient B cells without off-target deleterious effects, demonstrating its ability as a robust therapeutic for B cell-driven autoimmune disorders.